Idioma:

Prognostic Value of DNA Ploidy, bcl-2 and p53 in Localized Prostate Adenocarcinoma Incidentally Discovered at Transurethral Prostatectomy

Abaza, Ronney ; Diaz, Leslie K. ; Laskin, William B. ; Pins, Michael R.

The Journal of urology, 2006-12, Vol.176 (6), p.2701-2705 [Periódico revisado por pares]

Hagerstown, MD: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Prognostic Value of DNA Ploidy, bcl-2 and p53 in Localized Prostate Adenocarcinoma Incidentally Discovered at Transurethral Prostatectomy
Autor: Abaza, Ronney ; Diaz, Leslie K. ; Laskin, William B. ; Pins, Michael R.
Assuntos: adenocarcinoma ; Adenocarcinoma - genetics ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Disease Progression ; Flow Cytometry ; gene expression ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Incidental Findings ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Ploidies ; Prognosis ; prostate ; Prostatectomy ; Prostatic Diseases - surgery ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; transurethral resection of prostate ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland
É parte de: The Journal of urology, 2006-12, Vol.176 (6), p.2701-2705
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Discovery of prostatic adenocarcinoma limited to transurethral resection material generates a treatment dilemma. We investigated the usefulness of parameters shown to be associated with prognosis in prostate cancer (p53 and bcl-2 immuno-expression, DNA cell cycle analysis and Gleason score) to stratify these incidentally identified tumors to guide clinical decision making. Paraffin embedded tissues from transurethral prostate resection specimens containing T1a prostate adenocarcinoma from 44 patients who underwent resection between 1980 and 1990 were immunostained for p53 and bcl-2, and subjected to flow cytometry to determine DNA ploidy. Gleason score was determined by 2 pathologists independently. Statistical relationships among these 4 variables, tumor progression and cancer specific survival were analyzed. Six of 44 patients in the study population had cancer progression. Time to clinical progression was 4.5 years (range 7 months to 11 years). Most tumors stained negative for p53 and bcl-2. Only 2 tumors studied were aneuploid and neither of these 2 patients had cancer progression. Only Gleason score was a significant predictor of cancer progression on univariate and multivariate Cox regression analysis (p = 0.045 and 0.046, respectively). No tumor characteristics correlated with time to disease progression, including p53 and bcl-2 immuno-expression, and Gleason score (p = 0.182, 0.563 and 0.346, respectively). Positive immunostaining for p53 and bcl-2 did not occur together in the same tumor in significant fashion (p = 0.334), nor did either significantly occur more with aneuploidy (p = 0.237 and 0.307 respectively). For T1a prostate cancer incidentally detected on transurethral prostate resection p53 and bcl-2 immuno-expression, and DNA ploidy do not predict survival or disease progression.
Editor: Hagerstown, MD: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 4 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Prognostic Value of DNA Ploidy, bcl-2 and p53 in Localized Prostate Adenocarcinoma Incidentally Discovered at Transurethral Prostatectomy

Abaza, Ronney ; Diaz, Leslie K. ; Laskin, William B. ; Pins, Michael R.

Hagerstown, MD: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.